Cited by 257Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and LipoproteinsInflammatory Biomarkers in Disease Prognosis

Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes

Grossmann, Vera, Schmitt, Volker H., Zeller, Tanja, Panova-Noeva, Marina, Schulz, Andreas, Laubert-Reh, Dagmar, Juenger, Claus, Schnabel, Renate B. +8 more·2015·Diabetes Care

Abstract

OBJECTIVE: The inflammatory and immune systems are altered in type 2 diabetes. Here, the aim was to profile the immune and inflammatory response in subjects with prediabetes and diabetes in a large population-representative sample. RESEARCH DESIGN AND METHODS: In total, 15,010 individuals were analyzed from the population-based Gutenberg Health Study. Glucose status was classified according to HbA1c concentration and history of diagnosis. All samples were analyzed for white blood cells (WBCs), granulocytes, lymphocytes, monocytes, platelets, C-reactive protein (CRP), albumin, fibrinogen, and hematocrit. Interleukin-18 (IL-18), IL-1 receptor antagonist (IL-1RA), and neopterin concentrations were determined in a subcohort. RESULTS: In total, 7,584 men and 7,426 women were analyzed (range 35–74 years), with 1,425 and 1,299 having prediabetes and diabetes, respectively. Biomarkers showed varying dynamics from normoglycemic via subjects with prediabetes to subjects with diabetes: 1) gradual increase (WBCs, granulocytes, monocytes, IL-1RA, IL-18, and fibrinogen), 2) increase with subclinical disease only (lymphocytes and CRP), 3) increase from prediabetes to diabetes only (neopterin), and 4) no variation with glucose status (hematocrit). The strongest relative differences were found for CRP, IL-1RA, and fibrinogen concentrations. Several inflammatory and immune markers were associated with the glucose status independent from cardiovascular risk factors and comorbidities, varied with disease severity and the presence of disease-specific complications in the diabetes subcohort. CONCLUSIONS: The inflammatory and immune biomarker profile varies with the development and progression of type 2 diabetes. Markers of inflammation and immunity enable differentiation between the early preclinical and clinical phases of the disease, disease complications, and progression.

Integrity signals

Registry

Crossref · 10.2337/dc14-3008

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A German study of over 15,000 individuals documented a dose-response relationship between impaired glucose status and adipokine concentrations.

    “For example, a German study of over 15,000 individuals documented a dose- response relationship between impaired glucose status and adipokine concentrations 41 .”
  • Data from epidemiological studies indicate that circulating concentrations of proinflammatory adipokines are elevated in patients with T2DM.

    “Data from epidemiological studies indicate that circulating concentrations of proinflammatory adipokines are elevated in patients with T2DM.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Grossmann, V., Schmitt, V. H., Zeller, T., Panova-Noeva, M., Schulz, A., Laubert-Reh, D., Juenger, C., Schnabel, R. B., Abt, T. G. J., Laskowski, R., Wiltink, J., Schulz, E., Blankenberg, S., Lackner, K. J., Münzel, T., & Wild, P. S.
Affiliations
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • Universität Hamburg (DE)
  • Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany
  • Preventive Cardiology and Preventive Medicine, Department of Medicine 2, University Medical Center Mainz, Mainz, Germany
Corresponding author
Wild, Philipp S.
Venue
Diabetes Care
Published
2015-04-15
Volume
38
Issue
7
Pages
1356-1364
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2118744821
Cited by
257
References
6
Citations by year
2026: 13 · 2025: 26 · 2024: 25 · 2023: 22 · 2022: 33 · 2021: 30 · 2020: 30 · 2019: 21 · 2018: 20 · 2017: 18 · 2016: 9 · 2015: 10
FWCI
14.92
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Federal Ministry of Education and Research (BMBF 01EO1003)
  • Boehringer Ingelheim
  • Stiftung Rheinland-Pfalz für Innovation (AZ 961-386261/733)
  • Johannes Gutenberg-University of Mainz (Wissen schafft Zukunft/Center for Translational Va)
  • PHILIPS Medical Systems
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Keywords
type 2 diabetes, prediabetes, inflammation, immune response, inflammatory markers, C-reactive protein, fibrinogen, IL-18, interleukin-1 receptor antagonist, neopterin, leukocytes, disease progression, disease complications, HbA1c, Gutenberg Health Study
MeSH terms
Adult, Aged, C-Reactive Protein, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Immunity, Inflammation, Male, Middle Aged, Prediabetic State, Risk Factors, Biomarkers, Comorbidity, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review